EP1782067A1 - Dispositif de filtre, procede, kit et utilisation de celui-ci - Google Patents

Dispositif de filtre, procede, kit et utilisation de celui-ci

Info

Publication number
EP1782067A1
EP1782067A1 EP05754147A EP05754147A EP1782067A1 EP 1782067 A1 EP1782067 A1 EP 1782067A1 EP 05754147 A EP05754147 A EP 05754147A EP 05754147 A EP05754147 A EP 05754147A EP 1782067 A1 EP1782067 A1 EP 1782067A1
Authority
EP
European Patent Office
Prior art keywords
filter
filter device
sample
immunochemical
binding reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05754147A
Other languages
German (de)
English (en)
Inventor
Mika Saramäki
Aimo Niskanen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ani Biotech Oy
Original Assignee
Ani Biotech Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20040825A external-priority patent/FI20040825A0/fi
Application filed by Ani Biotech Oy filed Critical Ani Biotech Oy
Publication of EP1782067A1 publication Critical patent/EP1782067A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing

Definitions

  • the present invention relates to an immunochemical filter device, comprising a filter material attached to a support member, e.g. a cap of a vessel.
  • the filter material comprises a labeled specific binding reagent, which is activated by filtration of a liquid sample solution through the filter material.
  • the mixture of the sample solution and the labeled specific binding reagent is transferred to an analyzer device.
  • the invention further relates to use of such a filter device and to a process for determining the presence or absence of an analyte in a sample with a filter device of the invention.
  • a kit comprising the filter device is also provided.
  • the devices of the invention are especially suitable for home use, use at doctor's offices and/or by technically untrained staff, involving a minimal level of skills from the users.
  • a diagnostic device comprising a post-filter unit is known from US application
  • US 4,562,147 provides a radial immunodifiusion enzyme assay method for testing of pseudorabies antibodies in swine and other animals.
  • Agar test plates are provided including an underlying adherent coating of solubilized non-infectious swine pseudorabies antigen. The result of the test is obtained from the diameters of the resulting colored zones which correlate with the titers obtained by the official virus neutralization test.
  • EP 0 291 194 relates to assays involving specific binding, especially immunoassays and devices therefore.
  • the analytical test device comprises a hollow casing, containing a dry porous carrier, which communicates indirectly with the exterior of the casing via a bibulous sample receiving member.
  • the carrier contains in a first zone a labeled specific binding reagent and in a second zone spatially distinct from the first zone an unlabelled specific binding reagent for the same analyte.
  • the sample solution is contacted with the test device directly which increases the risk of overflow to the second zone.
  • EP 0284 232 provides a solid phase assay for determining the presence or absence of analyte in a liquid sample.
  • a test strip of the invention has a tracer movably supported on a first portion and a binder immobilized on a second portion.
  • a disadvantage of this method is that the sample solution is contacted with the test during the performance of the test, which increases the risk of overflow to the second portion.
  • EP 0250 137 describes an immunoassay using colloidal gold for detecting a ligand in a sample, where a membrane strip is contacted with a sample and simultaneously or successively with a liquid reagent containing a ligand binding partner or ligand labeled with colloidal gold.
  • a disadvantage of this method is that an additional liquid reagent containing the labeled ligand is needed.
  • WO 86/03839 illustrates a solid phase diffusion assay where the sample is first mixed with a labeled binding substance and then applied to a region of a support with immobilized adsorbent molecules and allowed to diffuse therein. The diffusion pattern is visualized and measured.
  • US 2003/0049857 relates to a diagnostic device comprising a test unit and a post-filter unit.
  • the post-filter unit comprises a label zone containing a dried indicator reagent.
  • the indicator reagent is drawn trough the post filter unit with a separate buffer and the sample is added directly to the test unit comprising the reaction zone. This however makes the test awkward to use.
  • test kits are available.
  • a wide variety of test kits are available commercially and many of them are intended for home use.
  • the test device is used as a sampling device or for collecting the sample there is a risk that the sensitive reagents and the structure of the analytical device is destroyed or disturbed. Further solid samples or liquid samples which need to be diluted require an additional step.
  • the present invention provides an improved detection system for immunochemical tests involving a filter device which enables a liquid sample with or without dilution or a diluted solid sample to be filtered through the device and the sample solution together with the labeled specific binding reagent to be transferred and mobilized from the filter material in a controlled manner.
  • the filter material of the filter device is not sintered. Due to the two-part system the analyzer device is not in direct contact with the liquid sample solution, thereby minimizing the possibilities that the reagents in and the structure of the analyzer device are destroyed or disturbed by the sampling procedure.
  • the device of the present invention is especially advantageous for tests where the sample need to be diluted.
  • the present invention provides an immunochemical filter device for performing an immunoassay comprising a filter material attached to a support member.
  • the filter material comprises a labeled binding reagent, preferably a labeled specific binding reagent which is activated by filtration of a liquid sample solution through the filter material, i.e. the labeled binding reagent is released from the filter material by migration of a liquid sample solution therethrough.
  • the support member is preferably a cap-like member that attaches in a liquid tight manner to a sample collection device, such as a tube.
  • a sample collection device such as a tube.
  • the labeled binding reagent/liquid sample solution is expressed from the cap (e.g., through an aperture, diffusible membrane or valve therein) for application to an analytical device (e.g., an immunochromatographic test strip having a binding reagent disposed thereon).
  • the filter device is part of a cap which is liquid tightly attachable to a vessel.
  • the liquid sample solution from the vessel alongside with the labeled specific binding reagent (preferably a reagent specific for analyte) released by contact with the sample from the filter material are transferred from the filter device to the analyzer device comprising lateral flow testing from which the positive or negative results are directly readable.
  • the result can be read directly visually (by naked eye) or by appropriate equipment capable of recording the results.
  • the sample solution may contain the sample as such or diluted with a buffer solution or extraction buffer.
  • An immunochemical process of the present invention for determining the presence or absence of an analyte in a sample solution comprises the steps of adding a sample to a vessel, attaching a filter device comprising a filter material attached to a support member liquid tightly to the vessel wherein the filter material comprises a labeled binding reagent, preferably a labeled specific binding reagent, filtering the sample through the filter material, contacting the mixture of the sample and the labeled specific binding reagent with an analyzer device and reading the result by detecting the presence or absence of said analyte in the analyzer device.
  • the labeled binding reagent is released.
  • the present invention further relates to a kit for determining the presence or absence of an analyte in a sample.
  • the kit comprises the test device of the invention and a vessel (e.g., a sample collection vessel) whereto the filter device is liquid tightly attachable.
  • the filter device comprises a filter material attached to a support member (e.g. a cap) wherein said filter material comprises a labeled binding reagent, preferably a labeled specific binding reagent.
  • an analyzer device comprising a porous carrier wherein said porous carrier lacks a labeled specific binding reagent may be part of the kit.
  • FIG. 1 is a side view of a filter device and a vessel in accordance with the invention.
  • FIG. 2 is a side view of a filter device and a vessel in accordance with the invention, where the vessel comprises a buffer solution.
  • FIG. 3 is a view seen from above of an analyzer device.
  • FIG. 4 is a view seen from above of another embodiment of the analyzer device.
  • the present invention relates to an immunochemical filter device for performing an immunoassay wherein the filter device comprises a filter material attached to a support member.
  • the filter material comprises a labeled specific binding reagent which is activated by filtration of a liquid sample solution through the filter material.
  • the labeled binding reagent preferably one specific for analyte, is released from the filter material by migration of the liquid sample through the filter material.
  • the support member is a cap of a vessel, for example a tube (e.g., a sample collection tube), and said cap is liquid tightly attachable to the tube.
  • Said cap preferably includes an aperture, diffusible membrane or valve through which liquid sample solution, after contact with labeled binding reagent, may be caused to flow from the filter device.
  • the invention further provides a detection system comprising an immunochemical filter device and an analyzer device, where the mixture of sample solution and labeled specific binding reagent or the reaction product (complex) formed thereof are added to the porous carrier of the analyzer device comprising a specific binding reagent optionally immobilized on the porous carrier.
  • a detection system comprising an immunochemical filter device and an analyzer device, where the mixture of sample solution and labeled specific binding reagent or the reaction product (complex) formed thereof are added to the porous carrier of the analyzer device comprising a specific binding reagent optionally immobilized on the porous carrier.
  • the liquid pressed from the filter device moves throughout the porous carrier of the analyzer device by diffusion and/or capillary action.
  • the liquid may be expressed from the filter device through an aperture, a diffusible membrane or a valve of the cap.
  • the present invention also relates to a kit for determining the presence or absence of an analyte in a sample, comprising a filter device comprising a filter material attached to a support member and a vessel whereto the filter device is liquid tightly attachable.
  • the filter material comprises a labeled specific binding reagent.
  • the immunochemical filter device enables a controlled mobilization and mixing of the labeled specific binding reagent with a potential analyte of the sample solution in the analyzer device comprising a porous carrier.
  • the labeled specific binding reagent is mobilized in a controlled manner when transferred to the analyzer device comprising a porous carrier.
  • the filter device also filters the sample, a sensitive and hygienic test is provided. Solid particles of a faeces sample or another solid sample will not penetrate or permeate the filter and will thus not block the pores of the analyzer device. If a vessel is used, the solid particles stay in the vessel thus providing a hygienic test.
  • the analytes to be detected can be disease specific antibodies including IgG, IgM and IgA, antibodies against Helicobacter pylori, Enterohaemorrhagic Escherichia coli (EHEC), Myoglobin, Troponin, Toxoplasma, Chlamydia trachomatis and pneumonia, Bordetella pertussis, Mycoplasma pneumoniae, Hepatitis A, B, C, HIV 1) , respiratory disorders or etc., autoantibodies against human proteins, viruses from faeces including Rota, Adeno, Parvo, Astro or Distemper, antigen tests from food or environmental samples including Enterohaemorrhagic Escherichia coli (EHEC), antigens excreted to serum including Myoglobin and Troponin, antigens excreted to urine including Luteinizing hormone (LH), Follicle stimulating hormone (FSH) and human chorionic gonadotropin (hCG) or to faeces including H.
  • pylori samples taken with a swab such as Group A Streptococci, Chlamydia antigen tests, Candida, Trichomonas or other antigens of or antibodies against bacteria, virus, fungi and parasites or components and products thereof.
  • a swab such as Group A Streptococci, Chlamydia antigen tests, Candida, Trichomonas or other antigens of or antibodies against bacteria, virus, fungi and parasites or components and products thereof.
  • the device and method of the invention may be used for a multitude of different tests including pregnancy, menopause, fertility, C-reactive protein (CRP), Thyroid stimulating hormone, toxoplasmosis, cancer antigen, respiratory disorder, bacteria, viruses, venereal diseases, celiac disease, allergy, myocardial infarct and drug tests, etc.
  • CRP C-reactive protein
  • the kit may further comprise a buffer solution wherein said buffer solution is added to the vessel in order to make the test kit ready to use or an analyzer device comprising a porous carrier wherein said porous carrier lacks a labeled specific binding reagent.
  • a sampling device for example a capillary, pipette or swab may be included.
  • lancets, alcohol pads and plasters may be included in the kit.
  • the sample can be urine, faeces, blood, serum, plasma, saliva, mucus, excretion from eyes or the sample solution may be a mixture of a sample and a buffer solution.
  • the present invention is advantageous for tests where the sample have to be diluted in order to perform a test. This does not require an additional step when the present invention is used since the sample may be added to a vessel already containing a suitable buffer solution. Further the sample is easy and hygienic to handle and the risk of contamination is decreased. Solid samples for example faeces are one example of samples which need to be diluted. Furthermore for example many whole blood samples such as finger tip samples (10 ⁇ l) usually have to be diluted 1/50 to 1/200 in order to be able to perform certain tests. This applies for instance to CRP-tests where the sample has to be diluted with a buffer solution in order to obtain a suitable sample solution.
  • the buffer of the buffer solution is chosen from buffers known in the art and depends on the detected analyte.
  • the pH is usually between 7 and 8,5 and the capacity of the buffer is sufficient to maintain the pH.
  • the buffer solution may further comprise additives in order to stabilize or increase or decrease other features of the buffer solution.
  • the buffer solution may be added to the vessel of the kit beforehand and can thus be included in a kit of the present invention.
  • the filter device of the present invention is especially advantageous for determining for example Helicobacter pylori.
  • the filter device is a filter tip comprising an antibody against H. pylori or an H. pylori antigen dried as a part of a conjugate solution on the filter material. If H. pylori antibodies are detected from whole blood or serum samples an H. pylori antigen is used and if the sample is faeces an antibody against H. pylori is added to the filter tip.
  • test device of the present invention is for determining celiac disease wherein the filter device in the form of a filter tip comprises a tissue protein or anti human IgA specific antibody against transglutaminase.
  • the filter device is dried to a moisture content of 8 % or less and packed hermetically separately or in combination with said analyzer device.
  • the construction of the filter device comprises the steps of; treating a filter material attached to a support member with a conjugate solution comprising a labeled specific binding reagent and optionally additives, and further drying, and packing the device.
  • the support member is provided with an aperture, diffusible membrane and/or valve (preferably one openable on application of gentle pressure; i.e., on pressure of the cap against the sample well of an analytical immunochemical device).
  • the filter material comprising the labeled specific binding reagent in one end is attached to a transparent cap, in which an aperture is disposed.
  • the filter device is attachable at an end opposing the aperture to a sample collection vessel.
  • a hydrophilic permeable material such as polyethylene, polyester, glass fiber and mixes thereof is selected.
  • the particle retention of the filter material is preferably 1 to 25 micrometer, more preferably 10 to 20 micrometer.
  • the filter material of the filter device is impregnated with a conjugate solution comprising a specific labeled reagent.
  • the whole material may be impregnated but preferably the conjugate solution is added in the middle of one side of the filter material and impregnated as a thin layer on top of the filter material.
  • the preferred amount of conjugate solution is 1 to 100 ⁇ l, preferably 10 to 40 ⁇ l. If the filter device comprises a filter tip or cap which is liquid tightly attachable to the vessel, the conjugate solution is dispensed at that end which is put inside the vessel.
  • the labeled specific binding reagent is obtained by coating the label particles with specific binding reagent(s) using methods well known in the art.
  • the specific reagents of the filter device and the analyzer device include antibodies, antibody fragments, recombinant antibodies, recombinant antibody fragments, antigens, lectins, receptors and/or ligands.
  • the label applicable in the filter device includes colored latex, gold, metal, dye, fluorogenic substances, superpara-magnetic particles coated with the specific binders. Chromogenic substances, particularly fluorochromogens and enzymatic labels may be used as markers as well. It is possible to use a combination of several different labeled specific binding reagents if the sample is detected for more than one analyte and the same specific binding reagent cannot be used for all.
  • the labeled specific binding reagent may be added to the filter material as such or as a conjugate solution further comprising additives for example natural or synthetic polymers such as albumin (BSA, Bovine serum albumin) and casein or PEG (polyethylene glycol), PVA (polyvinyl alcohol) and PVP (polyvinyl pyrrolidone), nonionic detergents such as TWEEN 20, HEXA (hexane sulphonic acid), TRITON-X-100, SDS and BRIJ and preservation agents such as sugar, for example glucose, sucrose and trehalose or derivatives thereof.
  • natural or synthetic polymers such as albumin (BSA, Bovine serum albumin) and casein or PEG (polyethylene glycol), PVA (polyvinyl alcohol) and PVP (polyvinyl pyrrolidone), nonionic detergents such as TWEEN 20, HEXA (hexane sulphonic acid), TRITON-X-100, SDS and BRIJ and
  • Additives are added as stabilizers in order to increase stability, in order to improve the release of labeled specific binding reagent and as blocking agents in order to make the reactive sites of the filter material inert when the test is performed and the conjugate solution is activated by a sample solution.
  • the conjugate solution may be applied by hand with a pipette or with an automated dispenser.
  • the filter device is dried in a dry room, with a relative humidity less than 20 % and further in a dry room with a relative humidity less than 8 %.
  • the filter device is then packed hermetically separately or in combination with an analyzer device, for example in a hermetic pouch.
  • the mixture of a sample solution and a labeled specific binding reagent may be transferred to an analyzer device, which is the result recording detecting device of the detection system.
  • the analyzer device may be prepared by immobilizing one or more specific binding reagents and optionally also control reagents directly or indirectly to a porous carrier of the device. The porous carrier is thereafter blocked.
  • the blocking solution a mixture comprising natural or synthetic polymers such as albumin (BSA, Bovine serum albumin) and casein or PEG (polyethylene glycol), PVA (polyvinyl alcohol) and PVP (polyvinyl pyrrolidone), nonionic detergents such as TWEEN 20, HEXA (hexane sulphonic acid), TRITON-X-100, SDS and BRIJ and preservation agents such as sugar, for example glucose, sucrose and trehalose or derivatives thereof, is prepared in order to make the reactive sites of the porous carrier inert.
  • natural or synthetic polymers such as albumin (BSA, Bovine serum albumin) and casein or PEG (polyethylene glycol), PVA (polyvinyl alcohol) and PVP (polyvinyl pyrrolidone), nonionic detergents such as TWEEN 20, HEXA (hexane sulphonic acid), TRITON-X-100, SDS and BRIJ and preservation agents such as sugar,
  • the porous carrier of the analyzer device is preferably selected from a group of materials consisting of nitrocellulose, paper, glass fiber, nylon, polyester, polysulphonate or cellulose and derivatives thereof and the porous carrier can optionally be placed on a backing and/or in a casing.
  • the analyzer device of the present invention differs from the conventional prior art devices in that it lacks the mobilizable labeled specific binding reagent.
  • the filter device can be used in connection with a analyzer device where the porous carrier comprises one porous passage, which may be penetrated by a sample solution, containing detection zone(s) but also with an analyzer device where the porous carrier comprises two or more channels optionally made by a suitable method comprising at least one specific binding reagent per channel, immobilized as a dot or zone.
  • a multiple channel device can be prepared by treating a porous material with a suitable method in order to get different channels for tests of different analytes (or controls). Thus several analytes can be detected from the same sample by one single test. Furthermore several detection zones per channel may be added in order to perform a semi- quantitative test.
  • the analyzer device may further comprise for example a sample pad comprising polyester or glass fiber.
  • the multiple channel device comprises a porous carrier processed by a water-repellency treatment or by laser in order to cause a network of channels where the tested sample can migrate. Different specific binding reagents may be bound in each channel.
  • Multiple channel analyzer devices have been described for example in PCT/FI2004/000179.
  • a multiple channel analyzer device is used in order to detect for several analytes from the same sample at the same time. Every channel of such device can thereto have several detection zones and/or control zones.
  • FIG. 1 represents a typical filter device and vessel.
  • a filter material 2 comprising a labeled specific binding reagent 3 in one end is attached to a transparent cap 1.
  • the filter device is attachable to a vessel 4.
  • FIG. 2 represents a typical filter device and vessel.
  • a filter material 2 comprising a labeled specific binding reagent 3 in one end is attached to a transparent cap 1.
  • the filter device is attachable to a vessel 4 containing a buffer solution 5.
  • FIG. 3 shows a typical analyzer device seen from above.
  • a casing 6 comprises a sample well 7 where the mixture of sample solution and conjugate solution is transferred.
  • the detection zone of the porous carrier is placed in the test window 8 and in case of a positive result a visible reaction can be seen there.
  • the control zone of the porous carrier is placed in the control window 9 where a visible reaction should be seen whenever the test is performed.
  • FIG. 4 shows another embodiment of an analyzer device.
  • Eight channels 10 are made by laser-etching a figure on a porous carrier such as nitrocellulose film. Treated areas 11 where markings concerning the tests and the manufacturer may be added during the laser treatment separate the channels.
  • Each channel 10 comprises a specific binder in a detection zone or dot 12. Also a place 13 (sample receiver) where the mixture of sample solution and conjugate solution should be transferred is shown.
  • Example 1 relates to detection of Streptococcus pyogenes from a throat swab.
  • a solution of a labeled specific binding reagent is prepared by reacting a gold solution and Streptococcus pyogenes specific antibodies. Further a conjugate solution comprising gold labeled antibodies in 0,01-0,5 M glysine buffer pH 7,5 to 8,5 with BSA (0,1-1,0 %), Tween 20 (0,01-0,05 %) and trehalose (0,5-1,5 %) is prepared and 20 ⁇ l of the conjugate solution is added to a POREX SQ-EASYTM filter tip comprising a high density polyethylene filter material with a particle retention of 15 ⁇ m. The solution is added to the filter material of the filter tip (the filter device of Fig. 1) using a pipette.
  • the filter tip is then left to dry in a dry room, with a relative humidity less than 20%.
  • the drying is continued in a dry room with a humidity of less than 8 %.
  • the analyzer device of Fig. 3 is constructed by immobilizing a Streptococcus pyogenes specific antibody on the porous carrier to form a detection zone.
  • a monoclonal antibody against the labeled specific binding reagent is immobilized on the carrier to form a control zone.
  • the nitrocellulose is then blocked with a blocking solution comprising BSA (0,1- 5,0%), TRITON-X-100, BRIJ and saccharose. The material is allowed to dry.
  • the porous carrier is placed in a casing.
  • a buffer solution (extract) is prepared by adding 4 drops of extract solution A; 1-3 M NaNO 3 and four drops of a extract solution B; 0,9 % NaCl pH 1-3 to a tube just before the sample is taken. Then the sample is taken from the throat using a swab and the swab is allowed to stand in the tube for two minutes after mixing. Then the swab is removed and the filter tip is attached to the tube.
  • sample solution Three drops (about 100-120 ⁇ l) of sample solution is pressed through the filter material and expressed therefrom into the sample well of the analyzer device.
  • the complex formed of the sample and labeled specific binding reagent is allowed to migrate for 5 minutes after which the result is read in the test window. If red lines are visible both in the detection zone of the test window and in the control zone of the control window, it indicates the presence of Streptococcus pyogenes in the sample.
  • Example 2 describes use of the invention for C-reactive protein (CRP) and Myoglobin testing.
  • CRP C-reactive protein
  • the sample is tested against CRP and Myoglobin using a multiple channel analyzer device.
  • the test for CRP is in one channel, the Myoglobin test in another and a control in a third channel.
  • a solution of labeled specific binding reagents is prepared by reacting a gold solution with C-reactive protein (CRP) specific antibodies and with Myoglobin specific antibodies.
  • CRP C-reactive protein
  • a conjugate solution comprising gold labeled antibodies in 0,01-0,5 M glysine buffer pH 7,5 to 8,5 with BSA (0,1-1,0 %), Tween 20 (0,01-0,05 %) and trehalose (0,5-1,5 %) is prepared and 40 ⁇ l is added to a high density polyethylene POREX SQ-EASYTM filter tip (filter device of Fig. 2) and the filter tip is then left to dry in a dry room, with a relative humidity less than 20%.
  • the analyzer device of with three separated channels is constructed by laser-etching the channels in a porous carrier of nitrocellulose and a mylard film. 0,5 ⁇ l of two different specific antibodies are immobilized on the porous carrier to form the detection zones in two channels of the analyzer device. An anti-mouse antibody for the labeled specific binding reagents is immobilized on the carrier in the third channel to form a control zone.
  • the material is allowed to dry before the nitrocellulose is blocked with a blocking solution comprising BSA, HEXA and trehalose.
  • the porous carrier is dried.
  • the amount of analyte to give a positive result is adjusted to 3 ⁇ l/ml for CRP and to 60 ng/ml for Myoglobin.
  • the test is performed by adding 200 ⁇ l of a modified PBS buffer, 1-5 mM EDTA and 100 ⁇ l of whole blood to a tube.
  • the filter device is attached to the tube and three drops of the mixture of sample solution and conjugate solution is pressed trough the filter material of the filter tip to that place of the analyzer device were the sample should be placed.
  • the sample and the labeled specific binding reagent are allowed to migrate for 5 minutes after which the result is read as visible dots in the control zone and in the detection zones, for samples where CRP and Myoglobin are present in amounts of 3 ⁇ l/ml and 60 ng/ml or more.
  • Example 3 describes use of the present invention for detection of virus antigens of
  • a solution of two different labeled specific binding reagents was prepared by reacting a latex solution with specific antigens for Rotavirus and Adenovirus.
  • 40 ⁇ l of a conjugate solution comprising the latex labeled antigens in 0,01-0,5 M glysine buffer pH 7,5 to 8,5 with BSA (0,1-1,0 %), Tween 20 (0,01-0,05 %) and trehalose (0,5-1,5 %) was prepared and added to a high density polyethylene POREX SQ-EASYTM filter tip. The filter tip was then left to dry in a dry room, with a relative humidity less than 20%. The drying is continued in a dry room with a humidity of less than 8 %.
  • the analyzer device with three separated channels was constructed by forming the channels in a porous carrier of nitrocellulose and a mylard film 0,5 ⁇ l of two different antibodies were immobilized on the porous carrier to form the detection zones in two channels of the analyzer device.
  • An anti-mouse antibody for the labeled specific binding reagents was immobilized on the carrier in the third channel to form a control zone. The reactive points of the channels were blocked and the analyzer device was dried.
  • 100 mg of a faeces sample was added to a tube comprising 900 ⁇ l of a PBS pH 7,7 buffer solution.
  • the sample and buffer solution was mixed and the filter tip was attached to the tube and the diluted sample and the conjugate solution of the filter device was pressed through the filter material and applied to the sample application spot of the analyzer device, from where the mixture diffused and migrated to the test zones, where a reaction took place if the sample contained the analyzable virus antigen and a visible dot or line could be seen.
  • EXAMPLE 4 Detection of Escherichia coli O157 and Ol 11 in food
  • Example 4 relates to a test for Enterohaemorrhagic Escherichia coli (EHEC).
  • the labeled specific binding reagent was prepared by reacting a gold solution and an E. coli O157 antibody.
  • the conjugate solution and the filter tip were prepared according to example 1.
  • An analyzer device comprising an E. coli O157 specific antibody in the detection zone was also prepared according to example 1.
  • the filter tip and the analyzer device were hermetically dried and packed in a pouch together with a pipette.
  • Pouches containing the devices were opened and 10 drops of the enriched samples were dispensed in tubes using a pipette. The filter tips were placed on the tubes. Three drops (approximately 110 ⁇ l) of sample solutions together with the conjugate of the filter devices were dispensed through the filter material into the sample window of the analyzer devices. The results were read 5 minutes after the application of the solution to the analyzer devices. Red lines were visible both in the detection zone of the test window and in the control zone of the control window, which indicated the presence of E. coli O157 in the sample. Positive and negative control samples were used to check proper performance of the tests. 10 drops of a positive control solution were added to a filtering tube and the testing was performed as described above. After 5 minutes two visible lines were detected in the detection window and the control window.
  • Example 5 relates to a test for celiac disease.
  • the labeled specific binding reagent was prepared by reacting a gold solution and a recombinant tissue fransglutaminase.
  • the conjugate solution and the filter tip were prepared according to example 1.
  • An analyzer device comprising an anti human IgA specific antibody in the detection zone was also prepared according to example 1.
  • the filter tip and the analyzer device were hermetically dried and packed in a pouch together with a tube containing 500 ⁇ l PBS buffer solution, a pipette, a lancet, an alcohol pad and a plaster.
  • Positive and negative control samples were used. 1 drop (10 ⁇ l) of blood was added to a filtering tube containing 500 ⁇ l of buffer solution. The filter tip was attached to the tube and 1 drop of sample solution was transferred through the filter material to the analyzer device. After 5 minutes two visible lines were detected. One of the lines was in the detection window and the other was in the control window.
  • Respectively 1 drop of a negative control solution were added to a filtering tube and the testing was performed as described above. Only one visible line was detected in the control window.
  • the alcohol pad is used to wash a finger tip from which a blood sample is taken using the lancet. 1 drop of blood is transferred to the tube with the pipette.
  • the test is performed as described above. Based on the above description it is evident that use of filter devices of the present invention increases security of the test results due to the more controlled mobilization of the labeled specific binding reagent.
  • Another advantage of the filter device is that tests can easily be performed for samples which need dilution and/or filtration. The samples may be added to a vessel already containing a buffer solution or an extraction buffer.
  • test system is easy to use it enables home use. Due to the fact that the analyzer device is not in direct contact with the liquid sample solution, overflow is avoided and an increased reliability of the test is obtained. Moreover the filter device and analyzer device of the invention are easy to store due to the fact that the devices are dried and that they are possible to store hermetically.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention fournit un dispositif de filtre immunochimique et l'utilisation de celui-ci, ledit dispositif de filtre comprenant un matériau filtre attaché à un élément support, par exemple un bouchon d'un récipient. Le matériau filtre comprend un réactif liant spécifique marqué, ledit réactif liant spécifique marqué étant activé par la filtration d'une solution d'échantillon liquide sur le matériau filtre. On transfère le mélange de la solution d'échantillon et du réactif liant spécifique marqué vers un dispositif analyseur comprenant un support poreux. On peut lire le résultat à partir d'une ou plusieurs zones de détection du dispositif analyseur, comprenant au moins un réactif liant spécifique, directement visuellement ou par un matériel approprié capable d'enregistrer les résultats. En plus l'invention fournit un procédé immunochimique servant à déterminer la présence ou l'absence d'un analyte dans une solution d'échantillon et en plus un kit comprenant le dispositif de filtre.
EP05754147A 2004-06-15 2005-06-15 Dispositif de filtre, procede, kit et utilisation de celui-ci Withdrawn EP1782067A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20040825A FI20040825A0 (fi) 2004-06-15 2004-06-15 Suodatinväline, sen käyttö, menetelmä ja kitti
US10/954,627 US8664001B2 (en) 2004-06-15 2004-09-29 Immunochemical filter device and methods for use thereof
PCT/FI2005/050215 WO2005124347A1 (fr) 2004-06-15 2005-06-15 Dispositif de filtre, procédé, kit et utilisation de celui-ci

Publications (1)

Publication Number Publication Date
EP1782067A1 true EP1782067A1 (fr) 2007-05-09

Family

ID=35509814

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05754147A Withdrawn EP1782067A1 (fr) 2004-06-15 2005-06-15 Dispositif de filtre, procede, kit et utilisation de celui-ci

Country Status (3)

Country Link
EP (1) EP1782067A1 (fr)
CA (1) CA2570383C (fr)
WO (1) WO2005124347A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4672263B2 (ja) * 2004-01-27 2011-04-20 デンカ生研株式会社 簡便な検出法、検出装置及び検出キットとその製法
US7749775B2 (en) 2006-10-03 2010-07-06 Jonathan Scott Maher Immunoassay test device and method of use
EP2264461A1 (fr) * 2009-06-19 2010-12-22 FZMB GmbH Forschungszentrum für Medizintechnik und Biotechnologie Dispositif d'exécution d'un test d'échantillon chromatographique d'affinité
CN103969251A (zh) * 2014-05-05 2014-08-06 湖北省食品药品监督检验研究院 一种集成化的化学反应快速检测装置及其方法
AU2015274660B2 (en) 2014-06-10 2020-07-16 Dxterity Diagnostics Incorporated Devices and methods for collecting and stabilizing biological samples

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0392377B1 (fr) * 1989-04-07 1995-02-15 Abbott Laboratories Méthode et appareil pour la séparation de plasma ou de sérum à partir du sang
US5252496A (en) * 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US6145688A (en) * 1996-07-17 2000-11-14 Smith; James C. Closure device for containers
US6162398A (en) * 1998-04-16 2000-12-19 Becton Dickinson And Company Assay device using shrink wrap
US6632681B1 (en) * 2000-07-24 2003-10-14 Ey Laboratories Reagent delivery device and method of use
WO2003098215A1 (fr) * 2002-05-16 2003-11-27 Medmira Inc. Dispositif de detection rapide d'anticorps de la vaccine, procede et kit d'essai y relatifs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005124347A1 *

Also Published As

Publication number Publication date
WO2005124347A1 (fr) 2005-12-29
CA2570383A1 (fr) 2005-12-29
CA2570383C (fr) 2015-04-14

Similar Documents

Publication Publication Date Title
US5416000A (en) Analyte immunoassay in self-contained apparatus
EP0319294B1 (fr) Examen de membrane utilisant l'application concentrée d'un échantillon
CN111164095B (zh) 用于改进分析物检测的测定方法
US6316205B1 (en) Assay devices and methods of analyte detection
JP4406510B2 (ja) 移動を阻止するために多孔度の減少を利用したアッセイ法
EP0823972B1 (fr) Dispositif et procede de diagnostic par detection
JP3506178B2 (ja) 対置部材クロマトグラフィー検定装置
JP2948318B2 (ja) 特異的結合アッセイ用の赤血球の分離方法
EP1723423A1 (fr) Dispositif d'echantillonnage et son procede d'utilisation
US20030045001A1 (en) Immunochromatographic test strip with arcuate sample application zone for ease-of-use in the field
AU2002330899A1 (en) Test strip for a lateral flow assay
WO2003008933A2 (fr) Bande d'essai pour dosage a ecoulement lateral d'un echantillon renfermant des cellules entieres
WO2007047924A2 (fr) Détection d'un ligand cible améliorée
US9207248B2 (en) Diagnostic detection devices and methods
US8664001B2 (en) Immunochemical filter device and methods for use thereof
JP3640278B2 (ja) アッセイ装置およびそれを用いるアッセイ方法
US20020036170A1 (en) Lateral flower plasma separation device
CA2570383C (fr) Dispositif de filtre, procede, kit et utilisation de celui-ci
JP3859027B2 (ja) 乳頭分泌液中の特定物質の測定方法
US20240077478A1 (en) System for rapid analysis of a capillary blood sample from a subject, intended for detecting the presence of at least one analyte in said capillary blood sample
MXPA97008428A (es) Dispositivo y metodo para la deteccion de diagnostico

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20071213

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091231